Skip to main content
. 2022 Jul 28;17(7):e0271795. doi: 10.1371/journal.pone.0271795

Fig 2. All-cause mortality associated with fungal secondary infections among COVID-19 patients who used AFT.

Fig 2

(A): All-cause mortality associated with AFT and without AFT in fungal secondary infections among COVID-19 patients; (B): All-cause mortality associated with mono- and combination AFT in fungal secondary infections among COVID-19 patients; (C): All-cause mortality associated with duration of AFT in fungal secondary infections among COVID-19 patients; (D): All-cause mortality associated with AFT and without AFT in patients with CAPA and (E): All-cause mortality associated with duration of AFT in patients with CAPA.